Yongming Liu

Dr. Yongming Liu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
DLDan Li
Dan Li
ZXZhaohui Xu
Zhaohui Xu
FWFeifei Wang
Feifei Wang
YHYinqin Hu
Yinqin Hu
XZXinyu Zhang
Xinyu Zhang
YLYongming Liu
Yongming Liu
Background: Carotid plaque and fatty liver disease, as important target organ damages of metabolic disorders, have undergone a steady increase in prevalence. Cholesterol, high-density lipoprotein, and glucose index (CHG), triglyceride–glucose index (TYG), and atherogenic index of plasma (AIP) are tools for assessing metabolic abnormalities. This research aimed to evaluate the potential of three indicators in predicting carotid plaque and fatty liver.Methods: This study is based on longitudinal health examination data from workers at Ansteel Group in China in 2019. The follow-up period was five years, with the outcomes being the occurrence of carotid plaque or fatty liver events. Multivariate Cox regression analysis was used to examine the relationship between CHG, TYG, and AIP with the outcomes of carotid artery plaque and fatty liver. We used restricted cubic spline (RCS) curves to analyze the dose-response relationship between the three indices and the outcomes. We employed receiver operating characteristic (ROC) curves to evaluate the predictive ability of these indices. Finally, we also conducted subgroup analyses.Results: Carotid plaque events developed in 659 workers (18.40%), and fatty liver in 375 workers (10.47%) during the follow-up period. Cox analysis revealed that the three indices were correlated with carotid plaque (Q3 vs Q1, CHG: HR 2.13, P < 0.001; TYG: HR 1.20, P = 0.006; AIP: HR 1.95, P < 0.001) and fatty liver (Q3 vs Q1, CHG: HR 2.46, P < 0.001; TYG: HR 1.75, P < 0.001; AIP: HR 3.47, P < 0.001). RCS indicated that the three indices were linearly related to carotid plaque and nonlinearly (inverted L-shaped) related to fatty liver. ROC curve analysis revealed that CHG had a stronger predictive ability for carotid plaque outcomes, while TYG had a stronger predictive ability for fatty liver. Subgroup analysis results showed that gender and BMI interacted with the three indicators in relation to outcomes.Conclusions: Our research found that CHG, TYG, and AIP were positively correlated with carotid plaque and fatty liver. Moreover, CHG demonstrated superior predictive ability for carotid plaque outcomes, whereas TYG demonstrated better performance for fatty liver outcomes.

22 April 2024 in Cardiology
Verified
Journal Article
Closed access
PDF file
ZXZhaohui Xu
Zhaohui Xu
YHYinqin Hu
Yinqin Hu
XSXinyi Shao
Xinyi Shao
TSTianyun Shi
Tianyun Shi
JYJiahui Yang
Jiahui Yang
YLYongming Liu
Yongming Liu
Introduction: Heart failure (HF) is a major global public health concern. The application of machine learning (ML) to identify individuals at high risk and enable early intervention is a promising approach for improving HF prognosis. We aim to systematically evaluate the performance and value of ML models for predicting HF prognosis. Methods: PubMed, Web of Science, Scopus, and Embase online databases were searched up to April 30, 2023, to identify studies on the use of ML models to predict HF prognosis. HF prognosis primarily encompasses readmission and mortality. The meta-analysis was conducted by MedCalc software. Subgroup analyses include grouping based on types of ML models, time intervals, sample sizes, the number of predictive variables, validation methods, whether to conduct hyperparameter optimization and calibration, data set partitioning methods. Results: A total of 31 studies were included. The most common ML models were random forest, boosting, support vector machine, neural network. The area under the receiver operating characteristic curve (AUC) for predicting HF readmission was 0.675 (95% CI: 0.651–0.699, p < 0.001), and the AUC for predicting HF mortality was 0.790 (95% CI: 0.765–0.816, p < 0.001). Subgroup analyses revealed that models with the prediction time interval of 1 year, sample sizes ≥10,000, the number of predictive variables ≥100, external validation, hyperparameter tuning, calibration adjustment, and data set partitioning using 10-fold cross-validation exhibited favorable performance within their respective subgroups. Conclusion: The performance of ML models in predicting HF readmission is relatively poor, while its performance in predicting HF mortality is moderate. The quality of the relevant studies is generally low, it is essential to enhance the predictive capabilities of ML models through targeted improvements in practical applications.

8 June 2025 in Archives of Medical Science
Verified
Journal Article
Open access
ZXZhaohui Xu
Zhaohui Xu
LLLi Letai
Li Letai
YHYinqin Hu
Yinqin Hu
JYJiahui Yang
Jiahui Yang
QWQiqi Wan
Qiqi Wan
YLYongming Liu
Yongming Liu
Introduction: This study aimed to evaluate trends in HHD mortality attributable to HBMI from 1990 to 2021 and projections up to 2040.Material and methods: Data on HHD mortality attributable to HBMI were obtained from the Global Burden of Diseases (GBD) 2021 database. Temporal trends in the burden of HHD attributable to HBMI were analyzed using generalized linear models to calculate the estimated annual percentage change (EAPC) in age-standardized mortality rates (ASMR) and age-standardized disability-adjusted life-years (DALYs) rates (ASDR) from 1990 to 2021.Results: From 1990 to 2021, the global ASMR for HHD attributable to HBMI increased from 6.83 (4.37 - 9.32) to 7.21 (4.23 - 9.94), with an EAPC value of 0.33 (0.27 - 0.39) for the ASMR. the ASDR increased from 144.72 (106.21 - 182.76) to 147.33 ( 109.06 - 183.45) with an EAPC value of 0.15 (0.1 - 0.21) for ASDR. Particularly severe ASMR and ASDR were observed in most countries in Africa and in a few countries along the Mediterranean coast. In contrast, most developed countries in North America, Europe, and Australia presented lower ASMR and ASDR. When the overall trend was divided into subsections, at the end of the study period, ASMR and ASDR for HHD attributable to HBMI showed a downward trend. By dividing the regions by SDI, middle SDI had the greatest fluctuation in ASMR and ASDR, and low SDI showed an increasing trend in ASMR and ASDR at the final joinpoint.Conclusions: Therefore, more targeted prevention approaches should be established to mitigate this growing trend.

8 December 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
ZXZhaohui Xu
Zhaohui Xu
JYJiahui Yang
Jiahui Yang
YHYinqin Hu
Yinqin Hu
QWQiqi Wan
Qiqi Wan
XWXinting Wang
Xinting Wang
YLYongming Liu
Yongming Liu

1 October 2025 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
ZXZhaohui Xu
Zhaohui Xu
YHYinqin Hu
Yinqin Hu
JYJiahui Yang
Jiahui Yang
QWQiqi Wan
Qiqi Wan
XZXinyu Zhang
Xinyu Zhang
YLYongming Liu
Yongming Liu
Heart failure with preserved ejection fraction (HFpEF) has a high prevalence and risk of mortality, which is still on the rise. Current drug therapies are ineffective, making the development of new drugs for HFpEF particularly important. Qifu Yixin prescription (QYP) has a 20-year history of treating HF, and we have observed positive clinical effects of QYP on HFpEF. However, high-level clinical evidence is lacking. Therefore, a standardized randomized controlled trial (RCT) is necessary to evaluate its clinical effectiveness and safety. This study was a randomized, double-blind, placebo-controlled, single-center trial. Participants with HFpEF were randomized in a 1:1 ratio to either the QYP or placebo group for a period of 12 weeks, according to a random number table. The follow-up period lasted for 12 weeks after drug discontinuation. The primary outcome was the change in NYHA classification from baseline to 24 weeks. Secondary outcomes include changes in NT-proBNP, BNP, echocardiographic indices, traditional Chinese medicine symptomatic score scale (TCMSSS), 6-minute walk test (6MWT), Minnesota living with heart failure questionnaire (MLHFQ), Kansas City cardiomyopathy questionnaire (KCCQ), HF readmission rate, cardiovascular mortality, and composite outcomes to evaluate the clinical effectiveness of QYP in treating HFpEF. The safety of QYP will be evaluated through blood, urine, and stool routine tests, liver and kidney function assessments, electrolytes, and electrocardiograms. This study will provide standardized, high-quality evidence-based medical support for the clinical application of QYP and facilitate the development of new drugs for HFpEF. http://www.chictr.org.cn . Trial number: ChiCTR2400088641. Registered on 22 Aug 2024.

21 May 2025 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
ZXZhaohui Xu
Zhaohui Xu
JWJincheng Wang
Jincheng Wang
JYJiahui Yang
Jiahui Yang
YHYinqin Hu
Yinqin Hu
MZMeng Zhang
Meng Zhang
YLYongming Liu
Yongming Liu
Cardiac fibrosis, characterized by excessive extracellular matrix deposition, is a critical contributor to cardiovascular diseases, including heart failure. Transforming growth factor-beta 1 signaling, especially through activin receptor-like kinase 5 (ALK5), plays a key role in cardiac fibroblast activation and fibrosis. Traditional drug discovery approaches face challenges in identifying ALK5 inhibitors. This study leverages computational methods to expedite the discovery of potential ALK5 inhibitors. An active learning model was trained to screen a vast compound library, resulting in the selection of promising candidates. Molecular fingerprint clustering analysis and the absorption, distribution, metabolism, excretion, toxicity evaluation further characterized these compounds. Machine learning-based quantitative structure - activity relationship models predicted their activity. Molecular dynamics simulations assessed binding stability in different environments. DE50349483 and DE21377883 emerged as promising candidates with potential inhibitory effects. This study showcases the power of computational methods in drug discovery, offering hope for innovative therapies in cardiac fibrosis.